Modeling Pharmacogenomics' Impact
Executive Summary
With the intuitive appeal of pharmacogenomics (PGX) now largely accepted, pharmaceutical companies are wrestling with whether and how to incorporate PGX information into their drug discovery, development, and marketing processes. Yet largely absent from the advocacy of the pharmacogenomicists is a detailed discussion of the impact PGX could have on market share and average drug revenues. Based on discussions with industry leaders and using data from markets for certain existing drugs, the authors, members of the consultancy AT Kearney, developed a set of assumptions and constructed a framework to quantify the impact of PGX on both the revenues of the average drug and on the overall size of the pharmaceutical market for a given indication.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.